当前位置： SCI文献检索 > Clinical Colorectal Cancer期刊下所有文献 > A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.

A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.

Abstract：

:This phase II study was designed to characterize the clinical activity of ISIS 3521 in patients with metastatic colorectal cancer (CRC). Sixteen patients with pretreated or refractory CRC were treated with ISIS 3521. Eleven patients were given a dose of 2.0 mg/kg per day, and 5 patients received 3.0 mg/kg per day given over 21 days followed by a 7-day rest period. Patients continued with study until evidence of disease progression or unacceptable toxicity was detected. Patients underwent baseline tumor biopsies followed by a second biopsy during the last week of the first 21-day infusion. All 16 patients underwent baseline tumor biopsies, and 12 of the 16 patients underwent on-study tumor biopsies. No evidence of tumor response was observed. One patient had stable disease after 2 cycles and remained on for 1 additional cycle only to demonstrate progression of disease at that time. No dose-limiting or other significant toxicities were observed at both dosages, which could not be explained by progression of disease. Fatigue was common in all patients treated but was not dose limiting, and there was no evidence of coagulopathy. Analysis of the tumor biopsies obtained from the 11 evaluable samples showed marked uptake of ISIS 3521 in the normal liver parenchyma. However, there was minimal uptake within the tumor cells. In addition, no evidence of any alteration in protein kinase C-a within the tumors or any downstream effects leading to apoptosis were observed. ISIS 3521 demonstrated no clinical activity or target modulation in refractory metastatic CRC.

journal_name

Clin Colorectal Cancer

journal_title

Clinical colorectal cancer

authors

Marshall JL,Eisenberg SG,Johnson MD,Hanfelt J,Dorr FA,El-Ashry D,Oberst M,Fuxman Y,Holmlund J,Malik S

doi

10.3816/ccc.2004.n.026

keywords:

subject

Has Abstract

pub_date

2004-11-01 00:00:00

pages

268-74

issue

4

eissn

1533-0028

issn

1938-0674

pii

S1533-0028(11)70127-X

journal_volume

4

pub_type

临床试验,杂志文章

相关文献

Clinical Colorectal Cancer文献大全
  • A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.

    abstract：INTRODUCTION:The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In this double-blinded, phase II trial, patients with mCRC who had not progressed after 6...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clcc.2018.02.004

    authors： Grávalos C,Carrato A,Tobeña M,Rodriguez-Garrote M,Soler G,Vieitez JM,Robles L,Valladares-Ayerbes M,Polo E,Limón ML,Safont MJ,Martínez de Castro E,García-Alfonso P,Aranda E,Spanish Cooperative Group for the Treatment of Digest

    更新日期：2018-06-01 00:00:00

  • Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.

    abstract：:Despite an armamentarium that is wide in range, scope of action, and target, chemotherapy has limited success in colorectal cancer (CRC). Novel approaches are needed to overcome tumor barriers to chemotherapy that includes an abnormal tumor vasculature constituting a poor drug delivery system. We have previously shown...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2009.n.025

    authors： Bhattacharya A,Tóth K,Sen A,Seshadri M,Cao S,Durrani FA,Faber E,Repasky EA,Rustum YM

    更新日期：2009-07-01 00:00:00

  • The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.

    abstract：BACKGROUND:Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS tumors. Although skin toxicities are the most common adverse events associated with EGFR in...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clcc.2011.06.004

    authors： Mitchell EP,Piperdi B,Lacouture ME,Shearer H,Iannotti N,Pillai MV,Xu F,Yassine M

    更新日期：2011-12-01 00:00:00

  • Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

    abstract：BACKGROUND:In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer. PATIENTS AND METHODS...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2006.n.037

    authors： Wolpin BM,Clark JW,Meyerhardt JA,Earle CC,Ryan DP,Enzinger PC,Zhu AX,Blaszkowsky L,Battu S,Fuchs CS

    更新日期：2006-09-01 00:00:00

  • Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.

    abstract：BACKGROUND:ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.06.009

    authors： Tosi F,Sartore-Bianchi A,Lonardi S,Amatu A,Leone F,Ghezzi S,Martino C,Bencardino K,Bonazzina E,Bergamo F,Fenocchio E,Martinelli E,Troiani T,Siravegna G,Mauri G,Torri V,Marrapese G,Valtorta E,Cassingena A,Cappello G

    更新日期：2020-12-01 00:00:00

  • Adjuvant radiation therapy of patients with rectal cancer.

    abstract：:The standard in rectal cancer has been to add adjuvant radiation therapy to surgery in patients with stage II and III disease. Total mesorectal excision has led to lower local recurrence rates, and, if properly performed, may make adjuvant radiation unnecessary for certain stage II and III patients, such as T3 N0 pati...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2003.n.002

    authors： Bechtel J,Tepper J

    更新日期：2003-02-01 00:00:00

  • Laparoscopic radical correction combined with extensive lymphadenectomy and pelvic autonomic nerve preservation for mid-to-low rectal cancer.

    abstract：OBJECTIVE:The purposes of this study were to confirm the definite metastasis and micrometastasis rate of upward and lateral lymph nodes of mid-to-low rectal cancer at stage II and stage III, and to evaluate the feasibility and safety of laparoscopic radical correction combined with extensive lymphadenectomy and pelvic ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2011.03.025

    authors： Liu T,Zhang C,Yu P,Chen J,Zeng D,Gan L,Lv W,Liu L,Yan X

    更新日期：2011-09-01 00:00:00

  • Interval colorectal cancer after colonoscopy.

    abstract：BACKGROUND:As more patients are screened for colorectal cancer a small but significant number of interval cancers develop after colonoscopy for colorectal cancer screening. MATERIALS AND METHODS:We reviewed records of 75,314 adult patients who underwent colonoscopy for screening or diagnostic purposes between 1998 and...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2014.11.001

    authors： Richter JM,Campbell EJ,Chung DC

    更新日期：2015-03-01 00:00:00

  • Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.

    abstract：BACKGROUND:Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancer pati...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2015.08.003

    authors： Sahin IH,Geyer AI,Kelly DW,O'Reilly EM

    更新日期：2016-03-01 00:00:00

  • Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

    abstract：PURPOSE:The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations. Capecitabine is also at least as effective as bolus 5-FU/LV i...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/ccc.2005.n.021

    authors： Twelves CJ,Butts CA,Cassidy J,Conroy T,Braud Fd,Diaz-Rubio E,Tabernero JM,Schoffski P,Figer A,Brunet R,Grossmann J,Sobrero AF,Van Cutsem EJ

    更新日期：2005-07-01 00:00:00

  • Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.

    abstract：BACKGROUND:The safety of bevacizumab in older mCRC patients is poorly understood. The purpose of this analysis was to determine the prevalence, incidence, and risk factors for treatment-related AEs in older bevacizumab recipients. PATIENTS AND METHODS:Patients age ≥65 were identified from SEER-Medicare and categorized...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2012.11.004

    authors： Shankaran V,Mummy D,Koepl L,Blough D,Yim YM,Yu E,Ramsey S

    更新日期：2013-09-01 00:00:00

  • Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.

    abstract：INTRODUCTION:Bevacizumab improves outcome for patients with advanced colorectal cancer (CRC) when added to chemotherapy. The HORIZON I trial resulted in similar outcome with bevacizumab or cediranib, a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor, as treatment of advanc...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clcc.2013.11.002

    authors： Bar J,Spencer S,Morgan S,Brooks L,Cunningham D,Robertson J,Jürgensmeier JM,Goss GD

    更新日期：2014-03-01 00:00:00

  • Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry.

    abstract：BACKGROUND:Colorectal cancer (CRC) is a common malignancy. There is growing evidence that CRC incidence is increasing in the younger population. There is controversy surrounding the prognosis of young patients with CRC. In this study we reviewed Australian patients with metastatic CRC (mCRC) who were younger than 40 ye...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2015.07.005

    authors： Vatandoust S,Price TJ,Ullah S,Roy AC,Beeke C,Young JP,Townsend A,Padbury R,Roder D,Karapetis CS

    更新日期：2016-03-01 00:00:00

  • Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.

    abstract：:Thymidylate synthase (TS) expression has been identified as an important predictor of response to 5-fluorouracil (5-FU). However, there is relatively little information on the heterogeneity of TS mRNA expression between primary and metastatic tumors, as well as differential expression of TS mRNA in metastatic sites. I...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2001.n.017

    authors： Yamada H,Ichikawa W,Uetake H,Shirota Y,Nihei Z,Sugihara K,Hirayama R

    更新日期：2001-11-01 00:00:00

  • Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

    abstract：BACKGROUND:The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. PATIENTS AND METHODS:Patients w...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clcc.2018.06.002

    authors： Shapiro JD,Thavaneswaran S,Underhill CR,Robledo KP,Karapetis CS,Day FL,Nott LM,Jefford M,Chantrill LA,Pavlakis N,Tebbutt NC,Price TJ,Khasraw M,Van Hazel GA,Waring PM,Tejpar S,Simes J,Gebski VJ,Desai J,Segelov E

    更新日期：2018-12-01 00:00:00

  • Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.

    abstract：:To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current trea...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2015.10.002

    authors： Goldstein DA,Zeichner SB,Bartnik CM,Neustadter E,Flowers CR

    更新日期：2016-03-01 00:00:00

  • Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.

    abstract：INTRODUCTION:In studies of colorectal cancer, the elderly have been frequently underrepresented because comorbid conditions and functional status often lead to study exclusion. For elderly patients with an indication for neoadjuvant chemoradiotherapy (nCRT), physicians usually decide using clinical factors whether nCRT...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.03.004

    authors： Jacobs L,van der Vlies E,Ten Bokkel Huinink D,Bloemendal H,Intven M,Smits AB,Weusten BLAM,Siersema PD,van Lelyveld N,Los M

    更新日期：2018-09-01 00:00:00

  • AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.

    abstract：BACKGROUND:The efficacy and safety of the FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In the context of a prospective single-arm trial (NC...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clcc.2018.06.003

    authors： Pentheroudakis G,Kotoula V,Koliou GA,Karavasilis V,Samantas E,Aravantinos G,Kalogeropoulou L,Souglakos I,Kentepozidis N,Koumakis G,Sgouros J,Zarkavelis G,Efstratiou I,Laschos K,Petraki C,Tikas I,Poulios C,Voutsina A,G

    更新日期：2018-12-01 00:00:00

  • Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.

    abstract：:Combination protocols of 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan or oxaliplatin have demonstrated high activity in metastatic colorectal cancer. Capecitabine, an oral 5-FU prodrug, may replace infusional 5-FU/LV in combination protocols with irinotecan or oxaliplatin. We therefore initiated a phase II stud...

    journal_title：Clinical colorectal cancer

    pub_type： 临床试验,杂志文章

    doi：10.3816/ccc.2004.n.009

    authors： Jordan K,Kellner O,Kegel T,Schmoll HJ,Grothey A

    更新日期：2004-05-01 00:00:00

  • Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders.

    abstract：BACKGROUND:The primary objective of this study was to determine the long-term outcome of sphincter preservation with preoperative radiation therapy (RT) and surgical resection in the treatment of distal rectal adenocarcinoma. PATIENTS AND METHODS:Between April 1988 and December 1996, 36 (cT2, n=9; cT3, n=27) patients ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2006.n.012

    authors： Rengan R,Paty PB,Wong WD,Guillem JG,Weiser M,Temple L,Saltz L,Minsky BD

    更新日期：2006-03-01 00:00:00

  • Positron emission tomography for the evaluation of patients with colorectal cancer.

    abstract：:Approximately 40% of patients treated with curative intent for colorectal carcinoma eventually recur. In about one third of these patients, the lesion is localized and potentially resectable. Typically, the recurrence is characterized by findings on diagnostic imaging studies and may be accompanied by a rise in the se...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2001.n.012

    authors： Fogarasi MC,Zelkowitz RS,Messana SA,Arrighi JA,Seibyl JP,Kummar S

    更新日期：2001-08-01 00:00:00

  • Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.

    abstract：BACKGROUND:Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age. PATIENTS AND...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.11.005

    authors： Gouverneur A,Coutureau J,Jové J,Rouyer M,Grelaud A,Duc S,Gérard S,Smith D,Ravaud A,Droz C,Bernard MA,Lassalle R,Forrier-Réglat A,Noize P,ETNA study group and the EREBUS study group.

    更新日期：2019-03-01 00:00:00

  • COVID-19 and the Global Impact on Colorectal Practice and Surgery.

    abstract：BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.05.011

    authors： Nunoo-Mensah JW,Rizk M,Caushaj PF,Giordano P,Fortunato R,Dulskas A,Bugra D,da Costa Pereira JM,Escalante R,Koda K,Samalavicius NE,Maeda K,Chun HK,ISUCRS COVID-19 Participating Investigator Group.

    更新日期：2020-09-01 00:00:00

  • Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

    abstract：:Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise infusional 5-fluorouracil (5-FU), leucovorin, and irinotecan or oxaliplatin. The fluoropyrimidine derivative capecitabine is at least as effective as 5-FU plus leucovorin bolus regimens. It displays a favorable toxicity profile and offer...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2008.n.015

    authors： Moosmann N,Heinemann V

    更新日期：2008-03-01 00:00:00

  • First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.

    abstract：BACKGROUND:Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. PATIENTS AND METHODS:Using a modified Simon accelerated titration design, adults with...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.08.003

    authors： Winer A,Denlinger CS,Vijayvergia N,Cohen SJ,Astaturov I,Dotan E,Gallant JN,Wang EW,Kunkel M,Lim B,Harvey HA,Sivik J,Korzekwa K,Ruth K,White K,Cooper HS,Ross EA,Zhou L,El-Deiry WS

    更新日期：2020-08-19 00:00:00

  • Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

    abstract：BACKGROUND:Individually, oxaliplatin and irinotecan have substantial activity in metastatic colorectal cancer (CRC) in combination with 5-fluorouracil/leucovorin. A combination regimen using all 4 agents could potentially increase response rates in CRC. PATIENTS AND METHODS:A multicenter phase II trial of oxaliplatin ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CCC.2007.n.017

    authors： McWilliams RR,Goetz MP,Morlan BW,Salim M,Rowland KM,Krook JE,Ames MM,Erlichman C

    更新日期：2007-05-01 00:00:00

  • Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.

    abstract：:Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States. Despite excellent prognosis for early stage disease, 5-year survival rates in metastatic disease remain low. A small subset of CRC is defined by a deficiency in mismatch repair (dMMR) resulting in high levels of micro...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2020.02.002

    authors： Thomas J,Leal A,Overman MJ

    更新日期：2020-06-01 00:00:00

  • Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016.

    abstract：BACKGROUND:Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC. MATERIALS AND METHODS:All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Nor...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.10.001

    authors： Guren MG,Aagnes B,Nygård M,Dahl O,Møller B

    更新日期：2019-03-01 00:00:00

  • Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer.

    abstract：:Epidermal growth factor receptor (EGFR) has been validated as an important target in the treatment of metastatic colorectal cancer (mCRC). While initial studies focused on the treatment of disease that was refractory to available chemotherapy agents, 2 recent themes have emerged: the use of KRAS mutation status to sel...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2010.s.006

    authors： Stein S,Cohen DJ,Hochster HS

    更新日期：2010-06-01 00:00:00

  • Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.

    abstract：BACKGROUND:Screening protocols for colorectal cancer are broadly recommended and effective in reducing mortality. However, populations from different age groups can harbor distinct pathologic and molecular profiles that can also be influenced by screening and polyp resection, especially in older ages. PATIENTS AND MET...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.06.004

    authors： Pereira AAL,Fernandes GDS,Braga GTP,Marchetti KR,Mascarenhas CDC,Gumz B,Crosara M,Dib L,Girardi D,Barrichello A,Seidler H

    更新日期：2020-12-01 00:00:00